<p>平台整合三种研究方式，针对胰腺癌肿瘤生物学的电气特性</p>
<p>, /PRNewswire/ -- <strong>(TSXV: PAIN) —</strong> Vector Science &amp; Therapeutics（“公司”）今天宣布提交了一项临时专利申请，涵盖一种新型基于导管的平台，旨在进行肿瘤内药物递送研究，初步科学重点为胰腺癌。该申请启动了一项前临床研究计划，探索在科学依据充分且未满足需求仍然显著的疾病中整合三种递送和激活方式。</p>
<p>胰腺癌是肿瘤学中研究最为深入且持续存在的未满足需求之一。约 80% 的患者在局部晚期或转移期被诊断（国家癌症研究所/NCI），此时手术不可行。尽管有可用的全身治疗方案，但该人群的五年生存率仍低于 5%（NCI），文献显示对局部递送策略的持续科学兴趣，作为全身方法的补充或替代。Vector 的临时专利描述了一种旨在推动该研究领域的平台架构。</p>
<p>该平台整合了三种研究方式：肿瘤内细胞分化剂的递送、基于肿瘤组织差异导电性的电消融，以及电引导化疗激活。</p>
<p><em>&#34;该平台中的三种方式都有现有文献作为基础。整合是新颖的。我们现在的工作是建立前临床证据，以确定这种整合是否能实现科学所建议的可能性。&#34;</em></p>
<p><strong>— Tom Bachinski，Vector Science &amp; Therapeutics 首席技术官</strong></p>
<p>临时专利申请的提交确立并保护了知识产权地位，前临床工作开始。公司的直接重点是原理验证：生成评估可行性、完善系统架构和支持未来监管及临床合作所需的基础数据。目前尚未为该特定平台生成或发布任何前临床或临床数据。</p>
<p><strong>关于 Vector Science &amp; Therapeutics</strong> Vector Science &amp; Therapeutics, Inc. 总部位于威斯康星州梅奎恩，开发新型生物机械设备和主动局部药物递送平台，以便为临床医生提供在精确性至关重要且全身风险不可接受的情况下的定点干预。公司的股票在多伦多创业交易所上市，代码为 PAIN。欲了解更多信息，请访问 www.vectorscience.co。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明，包括关于公司对产品的直接关注以及所描述技术的潜力的声明。这些声明涉及已知和未知的风险和不确定性。临时专利申请已提交，但尚未获得批准。无法保证临床或监管里程碑将在任何特定时间表上实现，或根本无法实现。前瞻性声明本质上是不确定的，实际表现可能受到许多重要因素、假设和期望的影响，其中许多超出了公司的控制，包括对公司的期望和假设。读者应谨慎对待在准备任何前瞻性声明时使用的假设可能会被证明是错误的。事件或情况可能导致实际结果与预测结果存在重大差异，原因是许多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制。读者还应谨慎对待任何前瞻性声明，不应过度依赖这些信息，因为尽管公司管理层在准备时认为这些信息合理，但可能会被证明是错误的，实际结果可能与预期存在重大差异。本声明中的信息截至本日期，Vector Science &amp; Therapeutics 不承担更新前瞻性声明的义务，除非法律要求。</p>
<p>多伦多创业交易所及其监管服务提供商（根据多伦多创业交易所政策中的定义）对本声明的充分性或准确性不承担责任。</p>
<p>来源：Vector Sciences &amp; Therapeutics</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz"/></p>

VTVT

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Vector Science & Therapeutics 已提交了一项临时专利，旨在开发一种新型微针导管平台，专注于肿瘤内药物递送，初步针对胰腺癌。该平台整合了三种模式：肿瘤内细胞分化剂递送、电消融和电引导化疗激活。此次专利申请标志着一项前临床研究计划的开始，旨在验证该技术的可行性并支持未来的监管合作。该公司旨在生成基础数据，以优化系统架构，尽管尚未发布任何前临床或临床数据</p>

<p>Platform Integrates Three Research Modalities Targeting the Electrical Properties of Tumor Biology in Pancreatic Cancer</p>
<div class="lb-trans"><p>平台整合三种研究方式，针对胰腺癌肿瘤生物学的电气特性</p>
</div><p>, /PRNewswire/ -- <strong>(TSXV: PAIN) —</strong> Vector Science &amp; Therapeutics (the &#34;Company&#34;) today announced the filing of a provisional patent application covering a novel catheter-based platform designed for intratumoral drug delivery research, with an initial scientific focus on pancreatic cancer. The filing initiates a preclinical research program exploring the integration of three delivery and activation modalities in a disease where the scientific rationale for localized, targeted intervention is well established and the unmet need remains significant.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- <strong>(TSXV: PAIN) —</strong> Vector Science &amp; Therapeutics（“公司”）今天宣布提交了一项临时专利申请，涵盖一种新型基于导管的平台，旨在进行肿瘤内药物递送研究，初步科学重点为胰腺癌。该申请启动了一项前临床研究计划，探索在科学依据充分且未满足需求仍然显著的疾病中整合三种递送和激活方式。</p>
</div><p>Pancreatic cancer represents one of oncology's most studied and persistent unmet needs. Approximately 80% of patients are diagnosed at a locally advanced or metastatic stage (National Cancer Institute/NCI), where surgery is not feasible. Despite available systemic regimens, five-year survival rates remain below 5% for this population (NCI), and the literature reflects sustained scientific interest in localized delivery strategies as a complement to or alternative to systemic approaches. Vector's provisional patent describes a platform architecture intended to advance that area of research.</p>
<div class="lb-trans"><p>胰腺癌是肿瘤学中研究最为深入且持续存在的未满足需求之一。约 80% 的患者在局部晚期或转移期被诊断（国家癌症研究所/NCI），此时手术不可行。尽管有可用的全身治疗方案，但该人群的五年生存率仍低于 5%（NCI），文献显示对局部递送策略的持续科学兴趣，作为全身方法的补充或替代。Vector 的临时专利描述了一种旨在推动该研究领域的平台架构。</p>
</div><p>The platform integrates three research modalities: intratumoral delivery of cell differentiation agents, electrical ablation based on the differential conductivity of tumor tissue, and electrically-guided chemotherapy activation.</p>
<div class="lb-trans"><p>该平台整合了三种研究方式：肿瘤内细胞分化剂的递送、基于肿瘤组织差异导电性的电消融，以及电引导化疗激活。</p>
</div><p><em>&#34;Each of the three modalities in this platform has a basis in the existing literature. The integration is novel. Our work now is to build the preclinical evidence that will determine whether that integration delivers what the science suggests is possible.&#34;</em></p>
<div class="lb-trans"><p><em>&#34;该平台中的三种方式都有现有文献作为基础。整合是新颖的。我们现在的工作是建立前临床证据，以确定这种整合是否能实现科学所建议的可能性。&#34;</em></p>
</div><p><strong>— Tom Bachinski, Chief Technology Officer, Vector Science &amp; Therapeutics</strong></p>
<div class="lb-trans"><p><strong>— Tom Bachinski，Vector Science &amp; Therapeutics 首席技术官</strong></p>
</div><p>The provisional patent filing establishes and protects the intellectual property position as preclinical work begins. The Company's immediate focus is on proof-of-principle validation: generating the foundational data required to assess feasibility, refine the system architecture, and support future regulatory and clinical collaboration. No preclinical or clinical data have yet been generated or published for this specific platform.</p>
<div class="lb-trans"><p>临时专利申请的提交确立并保护了知识产权地位，前临床工作开始。公司的直接重点是原理验证：生成评估可行性、完善系统架构和支持未来监管及临床合作所需的基础数据。目前尚未为该特定平台生成或发布任何前临床或临床数据。</p>
</div><p><strong>ABOUT VECTOR SCIENCE &amp; THERAPEUTICS</strong> Vector Science &amp; Therapeutics, Inc., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares are listed on the TSX Venture Exchange under the symbol PAIN. For more information, visit www.vectorscience.co.</p>
<div class="lb-trans"><p><strong>关于 Vector Science &amp; Therapeutics</strong> Vector Science &amp; Therapeutics, Inc. 总部位于威斯康星州梅奎恩，开发新型生物机械设备和主动局部药物递送平台，以便为临床医生提供在精确性至关重要且全身风险不可接受的情况下的定点干预。公司的股票在多伦多创业交易所上市，代码为 PAIN。欲了解更多信息，请访问 www.vectorscience.co。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements, including statements regarding the Company's immediate focus on the product, and the potential of the described technology. These statements involve known and unknown risks and uncertainties. The provisional patent application has been filed but has not been granted. No assurance can be given that clinical or regulatory milestones will be achieved on any particular timeline, or at all. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company, including expectations and assumptions concerning the Company. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by the management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The information in this release is provided as of the date hereof and Vector Science &amp; Therapeutics undertakes no obligation to update forward-looking statements except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括关于公司对产品的直接关注以及所描述技术的潜力的声明。这些声明涉及已知和未知的风险和不确定性。临时专利申请已提交，但尚未获得批准。无法保证临床或监管里程碑将在任何特定时间表上实现，或根本无法实现。前瞻性声明本质上是不确定的，实际表现可能受到许多重要因素、假设和期望的影响，其中许多超出了公司的控制，包括对公司的期望和假设。读者应谨慎对待在准备任何前瞻性声明时使用的假设可能会被证明是错误的。事件或情况可能导致实际结果与预测结果存在重大差异，原因是许多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制。读者还应谨慎对待任何前瞻性声明，不应过度依赖这些信息，因为尽管公司管理层在准备时认为这些信息合理，但可能会被证明是错误的，实际结果可能与预期存在重大差异。本声明中的信息截至本日期，Vector Science &amp; Therapeutics 不承担更新前瞻性声明的义务，除非法律要求。</p>
</div><p>Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release</p>
<div class="lb-trans"><p>多伦多创业交易所及其监管服务提供商（根据多伦多创业交易所政策中的定义）对本声明的充分性或准确性不承担责任。</p>
</div><p>SOURCE Vector Sciences &amp; Therapeutics</p>
<div class="lb-trans"><p>来源：Vector Sciences &amp; Therapeutics</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA49013&amp;Transmission_Id=202605010926PR_NEWS_USPR_____LA49013&amp;DateId=20260501"/></p>

09:26 ETVector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

prnewswire

vTv Therap

09:26 ETVector Science & Therapeutics 为一种用于肿瘤内药物输送的新型微针导管平台申请了临时专利